Octapharma USA appoints former Pfizer exec as VP of commercial marketing & development

Kelly Hearn, Octapharma USA, Vice President of Commercial Development & Marketing

Paramus-based Octapharma USA on Monday announced the appointment of pharmaceutical industry veteran Kelly Hearn as vice president of commercial development & marketing. She assumes immediate leadership of the product marketing team as the company continues to grow its presence in the U.S. market.

Octapharma USA is the American subsidiary of Switzerland-based Octapharma, one of the largest human protein manufacturers in the world.

During more than 20 years with Pfizer, Hearn has demonstrated impressive abilities to drive strategic expansion.

“Kelly Hearn brings to Octapharma USA an entrepreneurial spirit and a passion for developing and launching novel products to market that improve patient health outcomes,” Octapharma USA President Flemming Nielsen said. “During more than 20 years with Pfizer, Kelly has demonstrated impressive abilities to drive strategic expansion as well as operational excellence and transformation. We are pleased to welcome Kelly to our senior leadership team and look forward to her continued success.”

Hearn most recently served as Pfizer’s senior director of commercial development, where she drove pipeline strategy for infectious and rare diseases. During more than two decades with Pfizer, Hearn has led a variety of franchises both in the U.S. and globally, and most notably played an integral role in building the first channel and customer-centric hospital business unit for Pfizer.

“Octapharma USA has a talented and committed team of industry professionals focused on improving the lives of patients with genetic and acquired blood disorders,” Hearn said. “The company has an impressive history of developing innovative therapies that save and enhance patient lives, and I am thrilled to be a part of the team. I am excited to bring my diverse cross-therapeutic experience to the table and look forward to launching novel products that benefit patients while building the company’s U.S. pipeline.”